Pancreatic Cancer Research

ResearcherCornell UniversityActive in the last 2 years

Michael Ian D'Angelica

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-3731-0534; OpenAlex author ID A5009465403, A5111197614, A5121129968; NIH RePORTER profile ID 1900678. Sources: ClinicalTrials.gov.

Their work

Papers
39
Trials
1 (principal investigator on 1)
Grants
1
Labs led
0
Collaborators
134
Papers, trials and grants by year

2011: 1 paper · 2012: 5 papers · 2013: 2 papers · 2014: none · 2015: 1 paper · 2016: 1 paper · 2017: 1 paper, 1 trial · 2018: 4 papers · 2019: 1 paper, 1 grant · 2020: 1 paper · 2021: 5 papers · 2022: 5 papers · 2023: 2 papers · 2024: 2 papers · 2025: 7 papers · 2026: 1 paper

Papers 39

  1. Maximal Ablative Irradiation Because of Encasement for Patients With Locally Advanced Pancreatic Cancer: A Nonrandomized Clinical Trial. Co-author DOI 10.1001/jamasurg.2026.2988↗
  2. Influence of biologic sex and obesity on liver recurrence and survival in patients undergoing upfront surgery for pancreatic adenocarcinoma. Co-author DOI 10.1002/cncr.70088↗
  3. RNA neoantigen vaccines prime long-lived CD8+ T cells in pancreatic cancer. Co-author DOI 10.1038/s41586-024-08508-4↗
  4. Adjuvant modified FOLFIRINOX for resected pancreatic adenocarcinoma: clinical insights and genomic features from a large contemporary cohort. Co-author DOI 10.1093/jnci/djae269↗
  5. Genome-based classification of pancreatic acinar cell carcinoma reveals similarities to KRAS wild-type PDAC. Co-author DOI 10.1186/s12967-025-07381-7↗
  6. Impact of Financial Toxicity on Treatment Adherence and Quality of Life in Pancreatic Cancer. Co-author DOI 10.1200/op-24-00528↗
  7. Outcomes in Locally Advanced Pancreatic Cancer After Induction Ablative Radiation Therapy and Resection. Co-author DOI 10.1245/s10434-025-17199-8↗
  8. Radiomics in sporadic microsatellite instable, mismatch repair deficient and Lynch syndrome-associated pancreatic ductal adenocarcinoma: a pilot study. Co-author DOI 10.3389/fonc.2025.1584167↗
  9. Multi-parametric atlas of the pre-metastatic liver for prediction of metastatic outcome in early-stage pancreatic cancer. Co-author DOI 10.1038/s41591-024-03075-7↗
  10. Treatment Patterns and Outcomes in Pancreatic Cancer: A Comparative Analysis of Ontario and the USA. Co-author DOI 10.1245/s10434-023-14375-6↗
  11. Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. Co-author DOI 10.1038/s41586-023-06063-y↗
  12. Genomic Biomarkers Associated with Response to Induction Chemotherapy in Patients with Localized Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-22-3089↗
  13. Induction FOLFIRINOX for patients with locally unresectable pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/jso.26735↗
  14. Development and validation of the Massachusetts General Hospital/Memorial Sloan Kettering nomogram to predict overall survival of resected patients with pancre… Co-author DOI 10.1016/j.surg.2022.05.024↗
  15. Alterations in Somatic Driver Genes Are Associated with Response to Neoadjuvant FOLFIRINOX in Patients with Localized Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/xcs.0000000000000212↗
  16. Change in Neutrophil-to-Lymphocyte Ratio During Neoadjuvant Treatment Does Not Predict Pathological Response and Survival in Resectable Pancreatic Ductal Adeno… Co-author DOI 10.1177/0003134821989050↗
  17. Recurrence After Resection of Pancreatic Cancer: Can Radiomics Predict Patients at Greatest Risk of Liver Metastasis? Co-author DOI 10.1245/s10434-022-11579-0↗
  18. Treatment patterns and survival in patients with early-onset pancreatic cancer. Co-author DOI 10.1002/cncr.33664↗
  19. Preoperative CT predictors of survival in patients with pancreatic ductal adenocarcinoma undergoing curative intent surgery. Co-author DOI 10.1007/s00261-020-02726-w↗
  20. A Call for Caution in Overinterpreting Exceptional Outcomes After Radical Surgery for Pancreatic Cancer: Let the Data Speak. Co-author DOI 10.1097/sla.0000000000004471↗
  21. Local Control and Survival After Induction Chemotherapy and Ablative Radiation Versus Resection for Pancreatic Ductal Adenocarcinoma With Vascular Involvement. Co-author DOI 10.1097/sla.0000000000005080↗
  22. Toward an Optimized Staging System for Pancreatic Ductal Adenocarcinoma: A Clinically Interpretable, Artificial Intelligence-Based Model. Co-author DOI 10.1200/cci.21.00001↗
  23. Alterations in driver genes are predictive of survival in patients with resected pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/cncr.33038↗
  24. CT radiomics associations with genotype and stromal content in pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00261-019-02112-1↗
  25. Can physician gestalt predict survival in patients with resectable pancreatic adenocarcinoma? Co-author DOI 10.1007/s00261-017-1407-x↗
  26. The clinical utility of immunoglobulin G4 in the evaluation of autoimmune pancreatitis and pancreatic adenocarcinoma. Co-author DOI 10.1016/j.hpb.2017.09.001↗
  27. Extracellular matrix proteins and carcinoembryonic antigen-related cell adhesion molecules characterize pancreatic duct fluid exosomes in patients with pancrea… Co-author DOI 10.1016/j.hpb.2017.12.010↗
  28. Survival Prediction in Pancreatic Ductal Adenocarcinoma by Quantitative Computed Tomography Image Analysis. Co-author DOI 10.1245/s10434-017-6323-3↗
  29. Percutaneous Peritoneal Lavage for the Rapid Staging of Gastric and Pancreatic Cancer. Co-author DOI 10.1245/s10434-016-5757-3↗
  30. A Pilot Study Evaluating Serum MMP7 as a Preoperative Prognostic Marker for Pancreatic Ductal Adenocarcinoma Patients. Co-author DOI 10.1007/s11605-015-3057-z↗
  31. FOLFIRINOX Induction Therapy for Stage 3 Pancreatic Adenocarcinoma. Co-author DOI 10.1245/s10434-015-4647-4↗
  32. Hepatic arterial nodal metastases in pancreatic cancer: is this the node of importance? Co-author DOI 10.1007/s11605-012-2071-7↗
  33. Does pre-operative chemoradiation for initially unresectable or borderline resectable pancreatic adenocarcinoma increase post-operative morbidity? A case-match… Co-author DOI 10.1111/hpb.12033↗
  34. Operative procedures for unresectable pancreatic cancer: does operative bypass decrease requirements for postoperative procedures and in-hospital days? Co-author DOI 10.1111/j.1477-2574.2012.00477.x↗
  35. Survival after resection of pancreatic adenocarcinoma: results from a single institution over three decades. Co-author DOI 10.1245/s10434-011-1900-3↗
  36. Downstaging in pancreatic cancer: a matched analysis of patients resected following systemic treatment of initially locally unresectable disease. Co-author DOI 10.1245/s10434-011-2156-7↗
  37. Impact of obesity and body fat distribution on survival after pancreaticoduodenectomy for pancreatic adenocarcinoma. Co-author DOI 10.1245/s10434-012-2301-y↗
  38. A novel survival-based tissue microarray of pancreatic cancer validates MUC1 and mesothelin as biomarkers. Co-author DOI 10.1371/journal.pone.0040157↗
  39. Invasive carcinoma arising in intraductal papillary mucinous neoplasms of the pancreas: a matched control study with conventional pancreatic ductal adenocarcin… Co-author DOI 10.1097/sla.0b013e318214bcb4↗

Trials 1

  1. Does Cefoxitin or Piperacillin-Tazobactam Prevent Postoperative Surgical Site Infections After Pancreatoduodenectomy? Principal investigator NCT03269994↗

Grants 1

  1. Histopathologic validation of 89Zr-DFO-HuMab-5B1 PET/CT imaging in CA 19-9 positive pancreatic cancer R01CA222049↗

Closest collaborators

The 25 strongest of 134 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. William R. Jarnagin · 35 shared papers, 2011–2026 · strength 3.79
  2. Jeffrey A. Drebin · 19 shared papers, 2019–2026 · strength 2.90
  3. Alice Chia-Chi Wei · 17 shared papers, 2021–2026 · strength 2.79
  4. T. Peter Kingham · 25 shared papers, 2012–2025 · strength 2.67
  5. Vinod P. Balachandran · 19 shared papers, 2018–2026 · strength 2.65
  6. Kevin C. Soares · 14 shared papers, 2021–2026 · strength 2.42
  7. Eileen Mary O'Reilly · 15 shared papers, 2012–2026 · strength 1.90
  8. Anna M. Varghese · 9 shared papers, 2020–2026 · strength 1.34
  9. Peter J. Allen · 19 shared papers, 2011–2022 · strength 1.12
  10. Caitlin A. McIntyre · 8 shared papers, 2019–2025 · strength 0.95
  11. Wungki Park · 6 shared papers, 2020–2026 · strength 0.94
  12. Christopher H. Crane · 5 shared papers, 2021–2026 · strength 0.87
  13. T. Peter Kingham · 4 shared papers, 2025–2026 · strength 0.84
  14. Kenneth H. Yu · 5 shared papers, 2020–2026 · strength 0.71
  15. Marsha Reyngold · 3 shared papers, 2021–2026 · strength 0.55
  16. Richard Kinh Gian Do · 6 shared papers, 2015–2022 · strength 0.50
  17. Jayasree Chakraborty · 4 shared papers, 2018–2025 · strength 0.48
  18. Amber L. Simpson · 5 shared papers, 2018–2022 · strength 0.45
  19. Peter J. Allen · 3 shared papers, 2021–2025 · strength 0.43
  20. Alex B. Blair · 2 shared papers, 2025 · strength 0.43
  21. Quisette P. Janssen · 3 shared papers, 2022–2023 · strength 0.43
  22. Fiyinfolu O. Balogun · 2 shared papers, 2025–2026 · strength 0.39
  23. Marinela Capanu · 3 shared papers, 2020–2025 · strength 0.36
  24. Joshua S. Jolissaint · 2 shared papers, 2021–2025 · strength 0.34
  25. Lily V. Saadat · 2 shared papers, 2021–2024 · strength 0.31

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.